Journal
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 83, Issue 3, Pages 386-389Publisher
WILEY
DOI: 10.1038/sj.clpt.6100384
Keywords
-
Categories
Funding
- NIBIB NIH HHS [R21 EB005252, R21 EB005252-03, EB005252, R21 EB005252-02] Funding Source: Medline
- NINDS NIH HHS [R01 NS045062, R01 NS045062-03, NS045062, R01 NS045062-04] Funding Source: Medline
- NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R21EB005252] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS045062] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Human embryonic stem (ES) cells are an attractive tool for cell-based therapies because of their limitless capacity for proliferation and their ability to differentiate into all cell types of the body. However, these features introduce certain unique risks that must be considered in developing transplantation strategies for clinical use. We outline these risks and examine current approaches to address them, both before and after transplantation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
